In vivo studies have shown that PLGA@Icaritin nanoparticles enhance anti-tumor immunity by recruiting infiltrating CD4+ cells, CD8+ T cells, and immune factors such as IFN-γ, TNF-α, and IL-1 (93). This evidence concerns the gene CD8A and neoplasm.